Genitourinary Cancers | Tumor

Padcev Improves Outcomes for Cisplatin-Ineligible Bladder Cancer

June 6th 2024, 3:00pm

Article

For patients with cisplatin-ineligible bladder cancer, presurgical Padcev decreased the cancer stage without leading to delays in surgery.

A Poem About Finding Purpose and Looking Ahead During Cancer

June 5th 2024, 1:00pm

Article

Learning that I had cancer — melanoma and renal cell carcinoma — made me feel like I lost something, but I keep looking ahead.

Long-Term Postsurgical ADT May Reduce Prostate Cancer Metastasis Risk

June 4th 2024, 7:00pm

Article

Two years of postsurgical androgen deprivation therapy resulted in a 10-year metastasis-free survival rate of nearly 80%.

Words About Cancer Matter

May 28th 2024, 5:00pm

Article

During my time with cancer, I've come across words associated with cancer that I don't like and some that I appreciate.

Pluvicto May Slow Progression Earlier in Advanced Prostate Cancer

May 28th 2024, 3:00pm

Article

Treatment with Pluvicto following ARPI resulted in favorable progression and response outcomes in PSMA-positive mCRPR.

Lymph Node Radiation Reduced Death in Young Patients with Prostate Cancer

May 23rd 2024, 3:00pm

Article

Whole-pelvic radiation conferred a 67% lower risk of all-cause mortality among patients younger than 65 with unfavorable-risk prostate cancer.

Olivia Munn Has Hysterectomy After Breast Cancer, Michael McDonald’s Lesson from Wife’s Cancer and More

May 17th 2024, 3:00pm

Article

From Olivia Munn opening up about undergoing a hysterectomy and egg retrieval to Michael McDonald’s learned lesson after his wife’s cancer, here’s what’s going on in the oncology space this week.

Erleada, ADT ‘One-Two Punch’ in Prostate Cancer Treatment

May 16th 2024, 7:00pm

Article

The postsurgical combination of androgen deprivation therapy and Erleada has shown promising results in prostate cancer.

Most BCG-Unresponsive Bladder Cancer Responds to TAR-200 Treatment

May 8th 2024, 7:00pm

Article

A novel delivery system of gemcitabine called TAR-200 led to promising responses in certain patients with non-muscle-invasive bladder cancer.

FDA to Review Injectable Opdivo for All Approved Indications

May 8th 2024, 3:00pm

Article

The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.